GoHealth (NASDAQ:GOCO) Earns Sell (D-) Rating from Weiss Ratings

Key Points

• GoHealth (NASDAQ:GOCO) has received a "sell (D-)" rating from Weiss Ratings, indicating a negative outlook on the stock.
• Other analysts have mixed opinions, with Noble Financial maintaining an "outperform" rating, while Wall Street Zen downgraded their rating from "hold" to "sell."
• GoHealth recently reported quarterly earnings with a loss of ($1.23) per share, despite revenue of $94.05 million, which was below expectations of $119.76 million.

GoHealth (NASDAQ:GOCO - Get Free Report)'s stock had its "sell (d-)" rating restated by equities researchers at Weiss Ratings in a research report issued on Tuesday,Weiss Ratings reports.

Several other equities analysts have also recently weighed in on GOCO. Noble Financial reiterated an "outperform" rating on shares of GoHealth in a research report on Friday, August 8th. Wall Street Zen cut GoHealth from a "hold" rating to a "sell" rating in a research report on Friday, July 18th. Finally, Royal Bank Of Canada reduced their price target on GoHealth from $18.00 to $12.00 and set a "sector perform" rating for the company in a research report on Thursday, August 28th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, GoHealth has an average rating of "Hold" and a consensus price target of $12.00.

GoHealth Stock Performance

Shares of GOCO traded up $0.12 during mid-day trading on Tuesday, hitting $4.52. The stock had a trading volume of 9,736 shares, compared to its average volume of 56,886. The firm has a market cap of $129.17 million, a P/E ratio of -1.25 and a beta of 1.62. The business has a fifty day moving average price of $5.06 and a 200-day moving average price of $6.63. The company has a debt-to-equity ratio of 2.64, a current ratio of 1.56 and a quick ratio of 1.56. GoHealth has a 52 week low of $4.31 and a 52 week high of $21.00.

GoHealth (NASDAQ:GOCO - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($1.23) earnings per share for the quarter, beating the consensus estimate of ($2.60) by $1.37. The company had revenue of $94.05 million during the quarter, compared to analysts' expectations of $119.76 million. GoHealth had a negative return on equity of 8.74% and a negative net margin of 3.21%. On average, equities research analysts expect that GoHealth will post -5.5 EPS for the current year.

Institutional Investors Weigh In On GoHealth

Hedge funds have recently added to or reduced their stakes in the company. FNY Investment Advisers LLC bought a new stake in GoHealth during the first quarter worth about $31,000. N.E.W. Advisory Services LLC bought a new stake in GoHealth during the first quarter worth about $45,000. American Century Companies Inc. bought a new stake in GoHealth during the second quarter worth about $63,000. Bank of America Corp DE lifted its stake in GoHealth by 22.8% during the fourth quarter. Bank of America Corp DE now owns 7,831 shares of the company's stock worth $105,000 after purchasing an additional 1,452 shares during the last quarter. Finally, Cubist Systematic Strategies LLC lifted its stake in GoHealth by 297.3% during the first quarter. Cubist Systematic Strategies LLC now owns 10,915 shares of the company's stock worth $134,000 after purchasing an additional 8,168 shares during the last quarter. Institutional investors own 24.21% of the company's stock.

About GoHealth

GoHealth, Inc operates as a health insurance marketplace and Medicare-focused digital health company in the United States. The company operates a technology platform that leverages machine-learning algorithms of insurance behavioral data to optimize the process for helping individuals find the health insurance plan for their specific needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.